Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23535507 | 0.90 | FYN (0.48) | FYNMAPT | |
| SCHEMBL23535596 | 0.88 | RAB9A (0.53) | HPGDFYNLOXL2NPC1RAB9A | |
| SCHEMBL23535518 | 0.88 | FYN (0.45) | FYNMAPT | |
| SCHEMBL23535523 | 0.88 | FYN (0.49) | FYN | |
| SCHEMBL23547226 | 0.85 | FYN (0.43) | FYNMAPT | |
| SCHEMBL23535541 | 0.83 | NAMPT (0.50) | FYN | |
| SCHEMBL30014583 | 0.83 | NAMPT (0.50) | FYN | |
| SCHEMBL23535526 | 0.81 | POLB (0.55) | MAPTNPC1SMN1; SMN2POLB | |
| SCHEMBL30014341 | 0.81 | POLB (0.55) | MAPTNPC1SMN1; SMN2POLB | |
| SCHEMBL23535536 | 0.81 | HPGDS (0.49) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115768757-A | CD206 modulators and uses and methods of making thereof | 美利坚合众国,由健康及人类服务部部长代表 | 2023-03-07 | — | — | CN | disclosed |
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | US HEALTH (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4077297-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | CD209, MSR1, ARG1 | HPGD 1072/4885FYN 1874/4885MAPT 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.